Multidimensional Evaluation of Lisdexamfetamine: Pharmacology, Therapeutic Use, Toxicity and Forensic Implications.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or original empirical data
PubMed 41001763 · doi:10.1111/bcpt.70111
What was done
This narrative review summarizes the pharmacological mechanisms, clinical applications (such as attention-deficit/hyperactivity disorder and binge eating disorder), adverse effect profile, toxicity, and forensic implications of lisdexamfetamine based on existing literature.
What was found
The abstract reports no quantitative results, sample sizes, or effect estimates. It qualitatively describes lisdexamfetamine as an amino acid (lysine) coupled to d-amphetamine that undergoes enzymatic conversion to provide prolonged release, stimulating dopamine and noradrenaline release in the central nervous system. Documented adverse effects include insomnia, decreased appetite, weight loss, and xerostomia.
Why it matters
It provides a consolidated overview of the pharmacokinetics, therapeutic scope, and toxicological properties of lisdexamfetamine for clinicians, researchers, and policymakers.
Limits
The paper is a non-systematic narrative review containing no original data or quantitative meta-analyses. The abstract omits empirical metrics, effect sizes, statistical comparisons, and safety parameters.
Cited by
- supports Prescription stimulants such as Adderall and Vyvanse are amphetamines that primarily release catecholamines, mainly dopamine and epinephrine.